Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4560520 | 0.85 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL4558511 | 0.82 | MEN1 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL12459423 | 0.81 | SLC6A2 (0.66) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL2475580 | 0.81 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL3422142 | 0.81 | SLC6A2 (0.66) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL2722771 | 0.80 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL28239851 | 0.80 | SLC1A2 (0.41) | SLC6A4SLC6A2SLC6A3KDM4EMAPK1 | |
| SCHEMBL140633 | 0.76 | SLC6A3 (0.68) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL12702717 | 0.76 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C | |
| SCHEMBL8572147 | 0.72 | MAOB (0.49) | SLC6A4SLC6A2SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | SLC6A4 2834/4885SLC6A2 2953/4885SLC6A3 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.